FDA Approves Epcoritamab for R/R Follicular Lymphoma
The triplet regimen generated a 79% reduction in the risk of disease progression or death compared with rituximab plus lenalidomide alone.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.